Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Dec 2, 2025

VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up

Veracyte surges 27.5% after Q3 earnings and revenues beat estimates, driven by strong Decipher and Afirma test growth.

Zacks Investment Research • Nov 11, 2025

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Research Healthcare Conference – New York, NY Fireside Chat on November 17th at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference – London, UK Fireside Chat on November 20th at 11:30 a.m. Greenwich Mean Time Stephens Annual Investment Conference – Nashville, TN Fireside Chat on November 20t.

Business Wire • Nov 6, 2025

Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript

Veracyte, Inc. ( VCYT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO John Leite - Global Chief Commercial Officer Phillip Febbo - Chief Scientific & Medical Officer Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Puneet Souda - Leerink Partners LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Lu Li - UBS Investment Bank, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Benjamin Mee - Stephens Inc., Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Good day, and thank you for standing by.

Seeking Alpha • Nov 5, 2025

Veracyte Announces Third Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. “We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance,” said Marc Stapley, Veracyte's chief executive officer. “We continue to advance our mission of transforming cancer care by generat.

Business Wire • Nov 4, 2025

Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.19 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VYCT #AfirmaGRID--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research tool's ability to help define the future of thyroid nodule evaluation. Using the company's innovative whole-transcriptome-derived research-use-only platform, researchers analyzed molecular data from thyroid nodules to develop signatures with potential.

Business Wire • Nov 3, 2025

Veracyte (VCYT) Crossed Above the 20-Day Moving Average: What That Means for Investors

Veracyte (VCYT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VCYT crossed above the 20-day moving average, suggesting a short-term bullish trend.

Zacks Investment Research • Oct 16, 2025

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November 4, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and wi.

Business Wire • Oct 15, 2025

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Sep 29, 2025